Related Experiment Video

Updated: Jan 18, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors

Lin Wang1, Brian R Sardella2, Emily K Aronson1

  • 1Department of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.

NPJ Breast Cancer
|January 16, 2026
PubMed

Insights

A pulse of PARP inhibitor (PARPi) alone did not prevent BRCA1-related breast cancer in mice. Combining PARPi with an AKT inhibitor (AKTi) intercepted tumors but did not prevent new ones.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • BRCA1-related cancers are aggressive and linked to DNA repair deficiencies.
  • PARP inhibitors (PARPi) and AKT inhibitors (AKTi) show promise in treating these cancers.

Purpose of the Study:

  • To investigate if a pulse of PARPi alone or in combination with AKTi can prevent Brca1-related breast cancer.
  • To evaluate the efficacy of these treatments in a preclinical mouse model.

Main Methods:

  • Utilized a K14-Cre Brca1f/fTp53f/f mouse model.
  • Administered a pulse of PARP inhibitor (PARPi) ± an AKT inhibitor (AKTi).

Main Results:

  • PARPi monotherapy failed to prevent tumor development.
  • PARPi + AKTi combination therapy intercepted existing tumors but did not prevent new tumor formation.
  • These findings confirm treatment efficacy but not preventative capacity.

Conclusions:

  • While PARPi and AKTi combination shows efficacy in treating BRCA1/2-related tumors, it is insufficient for preventing carcinogenesis.
  • Further research is needed to develop strategies for complete cancer prevention in BRCA1-deficient contexts.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA108:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

15.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.3K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.0K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K